Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.66 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256154 | 0.92 | HSD11B1 (0.55) | HSD11B1HSD17B1HSD17B2MEN1ALDH1A1 | |
| SCHEMBL3254353 | 0.91 | HSD11B1 (0.60) | HSD11B1ALDH1A1KMT2ALMNA | |
| SCHEMBL3255541 | 0.91 | HSD11B1 (0.54) | HSD11B1HSD17B1HSD17B2KMT2ATDP1 | |
| SCHEMBL3258283 | 0.83 | HSD11B1 (0.43) | HSD11B1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL3621166 | 0.81 | HSD11B1 (0.70) | HSD11B1HSD17B1HSD17B2CYP2C19MEN1 | |
| SCHEMBL3248368 | 0.79 | HSD11B1 (0.41) | HSD11B1HSD17B1HSD17B2MEN1ALDH1A1 | |
| SCHEMBL3252155 | 0.79 | HSD11B1 (0.41) | HSD11B1MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL3251004 | 0.78 | HSD11B1 (0.40) | HSD11B1HSD17B1HSD17B2MEN1ALDH1A1 | |
| SCHEMBL4495095 | 0.76 | HSD11B1 (0.66) | HSD11B1HSD17B1HSD17B2CYP1A2CYP3A4 | |
| SCHEMBL6627313 | 0.76 | HSD11B1 (0.42) | HSD11B1MEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | claimed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | claimed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | claimed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7094792-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-08-22 | — | — | US | disclosed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | disclosed |
| WO-2004112782-A1 | NEW USE V | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1461325-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003043999-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885 |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.